SCM
KPTI icon

Silvant Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Silvant Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-759
Closed -$118K – 334
2021
Q2 		$118K Hold
759
– – 0.02% 220
2021
Q1 		$120K Hold
759
– – 0.02% 219
2020
Q4 		$176K Hold
759
– – 0.03% 193
2020
Q3 		$166K Buy
759
+521
+219% +$127K 0.03% 187
2020
Q2 		$68K Buy
+238
New +$70.4K 0.01% 238

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silvant Capital Management's KPTI Position: Q3 2021 in Review

Silvant Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q3 2021, closing a stake of 759 shares — an estimated $118K sold.

Silvant Capital Management first reported a position in KPTI in Q2 2020 and held it in 5 quarters. The position peaked at $176K in Q4 2020. 134 funds tracked by Wall St. Rank hold KPTI as of Q3 2021.

  • Silvant Capital Management reported no remaining Karyopharm Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Silvant Capital Management sold 759 Karyopharm Therapeutics shares in Q3 2021, an estimated $118K.
  • Silvant Capital Management first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 5 quarters.
  • Silvant Capital Management's Karyopharm Therapeutics position peaked at $176K in Q4 2020.
  • 134 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2021.

Based on Silvant Capital Management's 13F filing for Q3 2021, filed 8 Nov 2021.